Cancer Research Horizons opens nominations for its Innovation and Entrepreneurship Awards 2025
- January 8 2025
Cancer Research Horizons, the innovation arm of Cancer Research UK, has opened nominations for its Innovation and Entrepreneurship Awards 2025, which celebrate the UK’s most enterprising efforts in oncology by recognising the researchers and entrepreneurs who are making strides towards translating their innovations into effective treatments and diagnostics for the benefit of patients affected by cancer.
Nominations close on 17 March 2025 and can be submitted for multiple categories via self-nomination or by someone else. Nominations do not need to be funded by Cancer Research UK but must be based in the UK. All nominations will be reviewed by a judging panel of independent experts, which will be announced in the future. Award winners will receive funding, sector-wide recognition, and the chance to inspire the next generation of academic entrepreneurs.
All shortlisted nominees will be invited to attend a black tie gala dinner at Merchant Taylors’ Hall in London on 10 July 2025, where the winners will be announced. For team nominations, up to three representatives will be invited. The ceremony provides a unique opportunity to network with a range of rising stars, seasoned entrepreneurs, industry experts, and inspiring sector leaders.
The following five awards are open for nominations:
There will also be four special awards to recognise outstanding contributions to the academic cancer entrepreneurial field, which are not open to nominations; instead, the judging panel will select winners from shortlists identified by Cancer Research Horizons.
ENDS
About Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between academic research and taking drugs to market. We focus on the tougher, more profound ideas that can lead to true innovation, translating them into effective treatments and diagnostics for cancer patients.
To date, we've played an instrumental role in forming over 70 start-ups. We've helped bring 14 cancer drugs to market, borne out of Cancer Research UK's pioneering research. Through these drugs, we have enabled in excess of 6 million courses of treatment for cancer patients across the world.
With access to Cancer Research UK's network of 4,000 exceptional researchers, and £400m of annual research spend, we're a powerful partner in the fight to conquer cancer. By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, entrepreneurial development, data licensing and collaboration, spin-out creation, and offer a full spectrum of drug discovery and clinical capabilities.
Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered.
For more information and to get in touch with the team, visit cancerresearchhorizons.com.